PDT Partners LLC Buys 35,899 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)

PDT Partners LLC increased its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 12.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 316,281 shares of the company's stock after acquiring an additional 35,899 shares during the period. PDT Partners LLC owned about 0.21% of Adaptive Biotechnologies worth $1,896,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Adaptive Biotechnologies by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 10,714,888 shares of the company's stock worth $64,236,000 after purchasing an additional 75,448 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in Adaptive Biotechnologies by 17.0% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,370,919 shares of the company's stock valued at $20,209,000 after acquiring an additional 489,555 shares in the last quarter. Geode Capital Management LLC lifted its stake in Adaptive Biotechnologies by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 2,684,506 shares of the company's stock valued at $16,098,000 after acquiring an additional 22,628 shares during the last quarter. Voya Investment Management LLC grew its position in Adaptive Biotechnologies by 6,121.7% in the fourth quarter. Voya Investment Management LLC now owns 2,428,710 shares of the company's stock worth $14,560,000 after acquiring an additional 2,389,674 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Adaptive Biotechnologies by 12.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,604,876 shares of the company's stock worth $9,622,000 after purchasing an additional 183,881 shares during the last quarter. Institutional investors and hedge funds own 99.17% of the company's stock.

Adaptive Biotechnologies Stock Up 33.7 %

ADPT stock traded up $2.48 during mid-day trading on Friday, reaching $9.84. 15,566,433 shares of the stock traded hands, compared to its average volume of 1,546,287. The firm has a market capitalization of $1.49 billion, a PE ratio of -9.03 and a beta of 1.75. The business has a 50-day moving average of $7.76 and a two-hundred day moving average of $6.90. Adaptive Biotechnologies Co. has a 52 week low of $2.99 and a 52 week high of $10.28.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.08. The business had revenue of $52.44 million during the quarter, compared to analysts' expectations of $42.13 million. Adaptive Biotechnologies had a negative return on equity of 64.65% and a negative net margin of 89.12%. The firm's revenue was up 25.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.33) EPS. On average, equities research analysts anticipate that Adaptive Biotechnologies Co. will post -0.92 EPS for the current fiscal year.

Insider Transactions at Adaptive Biotechnologies

In related news, CEO Chad M. Robins sold 211,160 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $8.50, for a total value of $1,794,860.00. Following the completion of the transaction, the chief executive officer now directly owns 2,576,701 shares of the company's stock, valued at $21,901,958.50. This trade represents a 7.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Peter M. Neupert sold 10,000 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $7.05, for a total transaction of $70,500.00. Following the completion of the sale, the director now directly owns 224,690 shares in the company, valued at $1,584,064.50. This trade represents a 4.26 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 757,601 shares of company stock worth $6,040,624. Insiders own 6.20% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Scotiabank upped their price objective on shares of Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 13th. The Goldman Sachs Group upped their price target on Adaptive Biotechnologies from $9.00 to $10.00 and gave the stock a "buy" rating in a research note on Friday. Finally, Piper Sandler reissued an "overweight" rating and issued a $11.00 price objective (up from $7.00) on shares of Adaptive Biotechnologies in a research note on Thursday, February 20th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $9.60.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.